drugset / Trial / NCT01953835

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

NCT01953835

Phase 1 Completed 37 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a Phase I, two-part, open-label study designed to evaluate the effect of repeated doses of GSK2586184 on the pharmacokinetics (PK) of Simvastatin and Rosuvastatin in healthy volunteers (Cohort A), and to evaluate the pharmacokinetics of a new tablet formulation of GSK2586184 in healthy male volunteers (Cohort B). Cohort A is a single sequence drug interaction study in which 28 subjects (14 female and 14 male subjects) will be enrolled. Each subject will receive single doses of Simvastatin and Rosuvastatin on two occasions, once alone and once following administration of repeated doses of GSK2586184. Cohort B is a 3-way crossover PK study in which 9 male subjects will be randomized (3 subjects to each treatment sequence). Each subject will receive a single dose of the standard formulation of GSK2586184 with food and two doses of a new formulation of GSK2586184, once with food and once in a fasted state, according to their treatment sequence, with a 3-day wash out between doses. The primary aim of the study is to investigate the effects of GSK2586184 on the pharmacokinetics of the 2 statins and to assess the impact of dosing with and without food on a new formulation of GSK2586184 tablet.

Timeline

Start
2013-10-04
Primary completion
2014-03-10
Completion
2014-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg Oral
Subject SOLCITINIB Small molecule 400 mg Oral
Subject SOLCITINIB Small molecule 400 mg
Subject Simvastatin Small molecule 10 mg Oral